Cancer Genetics (CGIX) – Globe Newswire
-
Cancer Genetics and StemoniX Announce Merger Closing
-
Cancer Genetics and StemoniX Announce Merger Closing
-
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
-
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
-
Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development
-
Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development
-
Cancer Genetics to Present at the Annual 33rd ROTH Conference
-
Cancer Genetics to Present at the Annual 33rd ROTH Conference
-
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
-
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
-
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
-
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
-
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
-
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
-
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
-
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
-
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
-
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
-
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
-
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
-
Cancer Genetics Reports Third Quarter 2020 Financial Results
-
Cancer Genetics Reports Third Quarter 2020 Financial Results
-
Cancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
-
Cancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
-
Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million
-
Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million
-
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
-
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
-
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
-
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
-
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
-
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
-
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge
-
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge
-
Cancer Genetics Reports Second Quarter 2020 Financial Results
-
Cancer Genetics Reports Second Quarter 2020 Financial Results
-
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Issues Letter to Shareholders
-
Cancer Genetics Issues Letter to Shareholders
-
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update
-
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update
-
Cancer Genetics, Inc. Announces Strategic Transactions
-
Cancer Genetics, Inc. Announces Strategic Transactions
-
Cancer Genetics Announces 1-for-30 Reverse Stock Split
-
Cancer Genetics Announces 1-for-30 Reverse Stock Split
-
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
-
Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update
Back to CGIX Stock Lookup